Share on LinkedInShare on LinkedIn

ARTICLE · 11 APRIL 2022

Neurim Again! Final Injunctions - To Stay Or Not To Stay, That Was The Question

Marks & Clerk
Marks & Clerk
Contributor
Marks & Clerk

Marks & Clerk

Marks & Clerk LLP was founded in 1887 by George Croydon Marks, who was joined in partnership by...

View firm profile
Explore more from Marks & Clerk

In a recent decision the Court of Appeal has ordered a final injunction stayed pending the outcome of an appeal.

United KingdomIntellectual Property

In a recent decision the Court of Appeal has ordered a final injunction stayed pending the outcome of an appeal. In doing so it has provided insight into the factors that may be considered when determining whether damages may adequately compensate the party that prevails on appeal. It also gives practical guidance on how to manage such stay applications when the first instance court has refused permission to appeal.

Neurim Pharmaceuticals (1991) Ltd and another v Generics (UK) Ltd (trading as Viatris) and another [2022] EWCA Civ 370

Neurim Pharmaceuticals (1991) Ltd and another v Generics (UK) Ltd (trading as Viatris) and another  [2022] EWHC 512 (Pat)

 

Background

The Court of Appeal's ruling (handed down on 29 March 2022) is the most recent in the long-running dispute between Neurim and Mylan. Before discussing the detail of this decision it is necessary to go back to the start:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from